A COMPARATIVE STUDY OF EFFICACY AND SAFETY AMONG METFORMIN WITH SITAGLIPTIN, METFORMIN WITH VOGLIBOSE, AND METFORMIN WITH GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Kala P; Jamuna Rani R; Kumar Js

doi:10.22159/ajpcr.2017.v10i12.22050

Authors

Kala P Department of Pharmacology, SRM Medical College Hospital & Research Centre Potheri, Kattankulathur - 603 203, Kancheepuram, Tamil Nadu, India.
Jamuna Rani R Department of Pharmacology, SRM Medical College Hospital & Research Centre Potheri, Kattankulathur - 603 203, Kancheepuram, Tamil Nadu, India.
Kumar Js Department of General Medicine, SRM Medical College Hospital & Research Centre Potheri, Kattankulathur - 603 203,Kancheepuram, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2017.v10i12.22050

Keywords:

Diabetes, Fasting Plasma Glucose, Postprandial Plasma Glucose, Haemoglobin A1c Metformin, Sitagliptin, Voglibose, Glimepiride

Abstract

Objective: Type 2 diabetes mellitus (DM) is a most common metabolic disorder. The present study aimed to compare the efficacy and safety among metformin with sitagliptin, metformin with voglibose, and metformin with glimepiride in patients with type 2 DM.

Methods: This study was a prospective, randomized clinical trial study, conducted in patients attending the diabetology outpatient department of SRM Medical College Hospital and Research Center, Potheri, Kancheepuram, Tamil Nadu, from January 2013 to January 2014. The patients were randomized into three groups with 40 patients in each group. Fasting plasma glucose (FPG), 2 hrs postprandial plasma glucose (PPG), and hemoglobin A1c (HbA1c) level were assessed in all the patients before starting the treatment. In Group I, patients were prescribed metformin 500 mg with sitagliptin 50 mg, in Group II, patients were given metformin 500 mg with voglibose 0.2 mg, and in Group III, patients were put on metformin 500 mg with glimepiride 1 mg in the fixed combination. The outcome of the therapy was based on the level of improvement in the blood parameters.

Results: There was a significant reduction of FPG level seen in all three groups (p value - Group I <0.0001, Group II < 0.005, and Group III <0.0001). Group I and III showed significant reduction of PPG with p value <0.0001. There was a significant reduction of HbA1c seen in all the three groups (p<0.0001).

Conclusion: From the results of this study, it could be concluded that all the three groups were comparable in their efficacy.

Downloads

Download data is not yet available.

References

Unwin N, Whiting D, Gan D, Jacqmain O, Ghyoot G. IDF Diabetes Atlas. 4th ed. Brussels, Belgium: International Diabetes Federation; 2009.

Thankappan KR, Shah B, Mathur P, Sarma PS, Srinivas G, Mini GK, et al. Risk factor profile for chronic non-communicable diseases: Results of a community-based study in Kerala, India. Indian J Med Res 2010;131:53-63.

Viswanathan M, McCarthy MI, Snehalatha C, Hitman GA, Ramachandran A. Familial aggregation of Type 2 (non-insulin-dependent) diabetes mellitus in south India: Absence of excess maternal transmission. Diabet Med 1996;13(3):232-7.

Larsen PR. Williams Textbook of Endocrinology. 12th ed. Philadelphia, PA: Elsevier, Saunders; 2012. p. 1371-435.

Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus-progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 1999;281(21):2005-12.

Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363(15):1410-8.

Lamba HS, Bhargava CS, Thakur M, Bhargava S. Î± glucosidase and aldose reductase inhibitory activity in vitro and antidiabetic activity in vivo of Tribulus terrestris l. (Dunal). Int J Pharm Pharm Sci 2011;3(3):270-2.

Yada N, Thrulapati DT, Maheshwari A, Upadhyay V, Shah P. A study on the prescribing pattern of anti-diabetic drugs in a community clinic in Telangana state. Int J Pharm Pharm Sci 2015;7(9):222-6.

Lim S, An JH, Shin H, Khang AR, Lee Y, Ahn HY, et al. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in Type 2 diabetic patients: The cosmetic study. Clin Endocrinol 2012;77(2):215-23.

Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with Type 2 diabetes. Diabetes Obes Metab 2010;12(5):442-51.

Jeon HJ, Oh TK. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in Type 2 diabetic patients. Diabetes Metab J 2011;35(5):529-35.

Weitgasser R, Lechleitner M, Luger A, Klingler A. Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: Results of a 1.5-year follow-up study. Diabetes Res Clin Pract 2003;61(1):13-9.

Satoh N, Shimatsu A, Yamada K, Ogawa Y. Voglibose reduces arterial stiffness through lowering postprandial hyperglycemia in obese Type 2 diabetes. Diabetes 2007;56(1):173.

Takami K, Takeda N, Nakashima K, Takami R, Hayashi M, Ozeki S, et al. Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed Type 2 diabetes. Diabetes Care 2002;25(4):658-62.

Ismail TS, Deshmukh SA. Comparative study of effect of alpha glucosidase inhibitors-miglitol, acarbose and voglibose on postprandial hyperglycemia and glycosylated hemoglobin in Type-2 diabetes mellitus. Int J Pharm Bio Sci 2012;3(3):337-43.

Arechavaleta R, Seck T, Chen Y, Krobot KJ, Oâ€™Neill EA, Duran L, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with Type 2 diabetes inadequately controlled on metformin monotherapy: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metabol 2011;13:160-8.